Back to Search
SCOTT KAPLAN, PH.D.
PH.D.
Clinical Psychologist
NPI: 1174822019Individual
Specialties, Licenses & Credentials
Clinical PsychologistPrimary
Psychologist — Clinical
Code: 103TC0700X
071008091(IL)1915(KS)
Research & Publications (20)
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
PMID 19328538·Urology·2009
2-rct
Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms.
PMID 19302502·BJU Int·2009
4-observational
The role of MR imaging in detecting nodal disease in thyroidectomy patients with rising thyroglobulin levels.
PMID 19039052·AJNR Am J Neuroradiol·2009
8-other
Introduction: BPH and sexual dysfunction--recommendations for the primary care physician and urologist.
PMID 19002118·Int J Impot Res·2008
8-other
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial.
PMID 18639298·J Urol·2008
2-rct
Urinary retention and post-void residual urine in men: separating truth from tradition.
PMID 18485378·J Urol·2008
6-review
Current role of alpha-blockers in the treatment of benign prostatic hyperplasia.
PMID 19032603·BJU Int·2008
6-review
Commentary: Prevention of recurrent staphylococcal infections.
PMID 18756179·Pediatr Infect Dis J·2008
8-other
Antiretroviral therapy in HIV-infected patients with multidrug-resistant virus: applying the guidelines to practice.
PMID 19072099·AIDS Patient Care STDS·2008
6-review
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
PMID 18510659·BJU Int·2008
4-observational
[The role of muscarinic receptor antagonists in the treatment of men with lower urinary tract symptoms secondary to BPH].
PMID 17645086·Actas Urol Esp·2007
6-review
Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH.
PMID 17728048·Eur Urol·2007
6-review
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
PMID 17258855·Eur Urol·2007
2-rct
Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.
PMID 17592540·Rev Urol·2007
8-other
Identification of the patient with enlarged prostate: diagnosis and guidelines for management.
PMID 17620137·Osteopath Med Prim Care·2007
8-other
Impact of BAC limit reduction on different population segments: a Poisson fixed effect analysis.
PMID 17920837·Accid Anal Prev·2007
8-other
Duration of therapy with metoclopramide: a prescription claims data study.
PMID 17436356·Pharmacoepidemiol Drug Saf·2007
8-other
Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia.
PMID 17215996·Rev Urol·2006
8-other
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
PMID 17105794·JAMA·2006
4-observational
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
PMID 16904446·Urology·2006
2-rct
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 30 N MICHIGAN AVE STE 1820
CHICAGO, IL 60602 - Phone
- (312) 882-3344
Quick Facts
- NPI
- 1174822019
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile